Skip to main content
Erschienen in: Reactions Weekly 1/2020

01.09.2020 | Review

Increased lymphoma risk with anti-TNF agents and/or thiopurines in IBD

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

The use of anti-tumour necrosis factor (TNF) agents, alone or combined with thiopurines, in patients with inflammatory bowel disease (IBD) is associated with an increased risk of lymphoma. …
Literatur
Zurück zum Zitat Chupin A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics : 25 Aug 2020. Available from: URL: http://doi.org/10.1111/apt.16050 Chupin A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics : 25 Aug 2020. Available from: URL: http://​doi.​org/​10.​1111/​apt.​16050
Metadaten
Titel
Increased lymphoma risk with anti-TNF agents and/or thiopurines in IBD
Publikationsdatum
01.09.2020
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-83362-0

Weitere Artikel der Ausgabe 1/2020

Reactions Weekly 1/2020 Zur Ausgabe

Case report

Pembrolizumab

Case report

Pembrolizumab

Case report

Metronidazole

Case report

Pembrolizumab